Editas Medicine, Inc.

Editas did not give revenue or EPS figures on the call. Cash, cash equivalents and marketable securities were $318 million at June 30, 2024, versus $377 million at March 31, 2024. Management said the higher burn rate this quarter was due to increased external R&D, mainly clinical and manufacturing costs tied to faster reni-cel progress. The company expects existing cash plus near-term annual license fees and a contingent upfront payment under its Vertex license agreement to fund operating expenses and capital expenditures into 2026. For reni-cel, management said it expects additional clinical data from RUBY and EdiTHAL by year-end 2024 and still expects the future BLA package to be similar in patient number and follow-up to the gene editing medicine field, but it did not provide BLA filing timing guidance.

Gilmore O’Neill framed the quarter as one of continued momentum across the company’s three priorities: advancing reni-cel toward BLA/commercialization, building an in-vivo pipeline, and increasing business development around IP. He highlighted the June EHA data as supporting reni-cel as a potential best-in-class therapy, pointing to no vaso-occlusive events post-infusion, hemoglobin correction, high fetal hemoglobin, and faster engraftment. He also stressed that the in-vivo strategy is differentiated through functional upregulation rather than knockdown, and said the company is focused on capital efficiency and may consider partnering reni-cel to accelerate commercialization.

Erick Lucera said the company’s cash position was $318 million at June 30, down from $377 million at March 31, and that burn was somewhat higher because of increased external research and development tied to reni-cel clinical and manufacturing activity. He said that, together with near-term annual license fees and the contingent upfront payment under the Vertex license agreement, current resources should fund operations and capital expenditures into 2026. On business development, he reiterated that the company sees its Harvard, MIT and Broad IP as a strong base for bespoke licensing deals and a possible source of non-dilutive capital.

Analysts pressed on the timing and shape of the in-vivo proof-of-concept, and management said it will focus on biodistribution, editing efficiency, biomarker-based target modulation, and tolerability, while not yet disclosing the indication or tissue target. Questions on reni-cel centered on BLA readiness, adolescent cohort follow-up, and whether the late-2024 data could support broader labeling; management said it has not given filing timing guidance but is aligning with FDA on a package similar to Casgevy’s scale. Analysts also asked about launch lessons, fertility support, and ex-U.S. commercialization, and management said payer and center onboarding should improve by launch, fertility support remains important but is not affected in commercial settings, and partnering outside the U.S. remains an active option.